Liraglutide

Quick summary

Liraglutide is a once-daily injectable peptide that activates the GLP-1 receptor, a target shared by several glucose-lowering and weight-management drugs. It is sold under two brand names: Victoza (1.8 mg, for type 2 diabetes) and Saxenda(3.0 mg, for chronic weight management). Both are approved by the FDA, EMA, MHRA, TGA, and Health Canada.

In the LEADER cardiovascular outcomes trial, liraglutide reduced the risk of major adverse cardiovascular events (MACE) by 13 % in adults with type 2 diabetes and established cardiovascular disease or high risk, relative to placebo.^[1]In the SCALE Obesity and Prediabetes trial at 3.0 mg, participants lost a mean of approximately 8 % of body weight over 56 weeks, compared with 2.6 % on placebo.^[2]

The molecule has a half-life of approximately 13 hours, enabling once-daily dosing without the need for re-formulation for extended release. Like all approved GLP-1 receptor agonists, it carries a boxed warning for thyroid C-cell tumors based on rodent studies.^[4]

Discovery and development

Liraglutide was developed by Novo Nordisk and emerged from a programme to create GLP-1 analogs stable enough for once-daily use. Native GLP-1 is cleaved by the enzyme dipeptidyl peptidase-4 (DPP-4) within minutes of release into the circulation, giving it a plasma half-life of roughly two minutes. The challenge facing early GLP-1 analog programmes was to extend that half-life while maintaining receptor potency.

Liraglutide addressed this through two complementary modifications: an Arg34 substitution that removes a DPP-4 cleavage site, and attachment of a C16 fatty acid chain (palmitic acid) at lysine-26 via a gamma-glutamate spacer. The fatty acid allows non-covalent binding to serum albumin, creating a depot that slowly releases free peptide and slows renal clearance, extending the effective half-life to around 13 hours.

The FDA first approved liraglutide as Victoza for type 2 diabetes in January 2010 and as Saxenda for chronic weight management in December 2014. EMA approval for Victoza was granted in 2009 and Saxenda in 2015.^[4],[5],[6]

Structure

Liraglutide is a 31 amino-acid peptide with a molecular weight of approximately 3,751 daltons. Its sequence differs from human GLP-1(7-37) at two positions:

• Arg34 substitution: a lysine at position 34 of native GLP-1 is replaced by arginine. This change eliminates a potential DPP-4 cleavage site and also prevents unwanted amidation reactions during manufacturing.
• C16 fatty acid at Lys26: a palmitic acid (C16) moiety is attached to the epsilon-amino group of lysine-26 via a gamma-glutamate linker. This lipid arm promotes reversible binding to serum albumin, the principal mechanism of extended half-life.

The result is a peptide that retains the receptor-binding characteristics of human GLP-1 while resisting DPP-4 cleavage and achieving a half-life long enough for once-daily dosing.

Mechanism of action

Liraglutide activates the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed on pancreatic beta cells, in the gastrointestinal tract, the heart, and in specific regions of the brain including the hypothalamus and brainstem. Activation of GLP-1R has several downstream effects that are relevant to its clinical use:

• Glucose-dependent insulin secretion: GLP-1R activation on beta cells stimulates insulin release only when blood glucose is elevated, which substantially lowers the risk of hypoglycaemia relative to insulin or sulfonylureas.
• Glucagon suppression: liraglutide suppresses glucagon secretion from alpha cells in a glucose-dependent manner, reducing hepatic glucose output.
• Gastric emptying: slowed gastric emptying extends the time before postprandial glucose appears in the bloodstream, blunting glucose excursions after meals.
• Appetite and satiety: central GLP-1R signaling in hypothalamic and brainstem nuclei reduces appetite and increases satiety, which accounts for the weight-reducing effect seen at both the 1.8 mg and 3.0 mg doses.

Pharmacokinetics in summary

• Subcutaneous bioavailability: approximately 55 %.^[4]
• Time to peak (Tmax): 8–12 hours after subcutaneous injection.
• Half-life (t½): approximately 13 hours, supporting once-daily dosing. Steady-state is reached in 2–3 days.^[7]
• Volume of distribution: approximately 11–17 L, consistent with albumin binding and limited distribution beyond plasma.
• Metabolism: proteolytic degradation of the peptide backbone; no evidence of hepatic CYP450 involvement. The C16 fatty acid moiety undergoes beta-oxidation.
• Renal excretion: intact liraglutide is not recovered in urine. Renal impairment has a modest effect on exposure and dose adjustment is not routinely required, but data in severe impairment are limited.

Clinical evidence

Two programmes form the core of liraglutide's clinical evidence base: the LEAD programme (type 2 diabetes efficacy and safety), the LEADER cardiovascular outcomes trial, and the SCALE programme (weight management).

LEADER established GLP-1 receptor agonist cardiovascular benefit before the class generalisation was extrapolated to other agents, giving liraglutide a specific CV outcomes label in patients with established atherosclerotic cardiovascular disease or high risk.^[1]

Safety overview

The most common adverse effects across pivotal trials were gastrointestinal: nausea, diarrhea, and vomiting, predominantly mild to moderate in severity and most frequent during dose escalation. Nausea affects a substantial minority of patients during the initiation period and often attenuates within the first few weeks.^[4],[5]

The product label carries a boxed warning for the risk of thyroid C-cell tumors, based on dose- and duration-dependent findings in rodents. The relevance of this rodent signal to humans is uncertain; the FDA and EMA consider the risk unresolved. Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.^[4]

Other notable safety signals include a modest increase in resting heart rate (approximately 2–4 bpm in trials), pancreatitis (rare; causality not definitively established), and cholelithiasis. Hypoglycaemia risk is low when liraglutide is used without concomitant insulin or sulfonylureas.

Approved indications and regulatory status

Liraglutide is among the most widely approved GLP-1 receptor agonists globally. It holds regulatory approval in all five jurisdictions covered by this hub:

• United States (FDA): Victoza (1.8 mg, T2DM, 2010); Saxenda (3.0 mg, chronic weight management, 2014).^[4],[5]
• European Union (EMA): Victoza (T2DM, 2009); Saxenda (weight management, 2015).^[6]
• United Kingdom (MHRA): Both brand names approved, retained post-Brexit. NICE has issued guidance covering both indications.
• Australia (TGA): Victoza and Saxenda approved.
• Canada (Health Canada): Victoza and Saxenda approved.

Use the region switcher in the page header for agency-specific indication details, including any local prescribing restrictions.